IDH2 and acute myeloid leukemia: IDH2 inhibitor (Enasidenib or AG‐221) and IDH1 inhibitor (Ivosidenib or AG‐120) have been approved by the Food and Drug Administration in the United States for targeted therapy of AML.6, 7